Cigarette smoke inhalation stimulates dopaminergic neurons in rats.

In humans, nicotine is self administered by inhalation of tobacco smoke as opposed to animal models, where nicotine is administered via systemic injection. The aim of the present study was to clarify whether tobacco smoke inhalation would affect dopaminergic projections differently from the reported activation after the systemic administration of nicotine. For this purpose, tobacco smoke from cigarettes containing 1.0 or 0.1 mg nicotine was delivered by inhalation to rats, while recording from antidromically identified nigrostriatal and mesolimbic dopamine neurons. Smoke inhalation from 1.0 mg nicotine cigarettes caused a peculiar abrupt increase of discharge activity of mesolimbic dopamine neurons, while nigrostriatal cells were less responsive. This activation was promptly antagonized by mecamylamine (2.0 mg/kg, i.v.). In contrast, smoke delivered from 0.1 mg nicotine cigarettes was ineffective. These findings suggest that the boosting activation of mesolimbic dopamine neurons by inhaled nicotine might be relevant for the rewarding properties of tobacco smoking and also for the effectiveness of new treatments to stop smoking.

Failure of acute diphenylhydantoin to affect the spontaneous electrical activity of dopamine cells.

Diphenylhydantoin (DPH) has recently been reported to produce dopaminergic (DA) supersensitivity in animals. These results have suggested that the dyskinesias observed in humans after DPH, although rare, might be regarded as a neuroleptic-like effect. Indeed dyskinesias would be induced by an inactivation of post-synaptic DAergic receptors, operated by DPH, and therefore reminiscent of that observable in neuroleptic treatment. In order to investigate this matter, we studied the effects of i.v. DPH on the extracellular single unit activity of DAergic cells located in mid-brain areas of rats. DPH was injected alone or in combination with DA antagonists such as L-sulpiride (L-SULP) and haloperidol (HAL), or the DAergic agonist apomorphine (APO). Our results show that DPH did not affect spontaneous DAergic firing rate and also failed to modify the known action of the DA agonists and antagonists which were tested on these neurons.

Reduction of reticulata neuronal activity by zolpidem and alpidem, two imidazopyridines with high affinity for type I benzodiazepine receptors.

Zolpidem and alpidem, two imidazopyridines with high affinity for the type I benzodiazepine recognition site, have recently been proposed as preferential hypnotic (zolpidem) and anxiolytic (alpidem) drugs notable for the minor incidence of side-effects. To further characterize the molecular mechanism involved in the action of these drugs, we studied their effects in comparison with those of diazepam on the spontaneous electrical activity of substantia nigra pars reticulata (SNR) neurons. These cells have been shown to be extremely sensitive to various positive and negative modulators of GABAergic transmission. All three drugs consistently produced a dose-dependent (0.03-8.0 mg/kg i.v.) inhibition of the firing of SNR cells when administered as a single bolus. However, zolpidem was more potent and efficacious than diazepam or alpidem. The ID50s were 0.076, 0.492 and 0.821 mg/kg, respectively. When the drugs were injected in exponentially (ratio 2) increasing doses up to 8.0 mg/kg, the rank order for tachyphylaxis was zolpidem much greater than diazepam greater than alpidem. Since the effects of the drugs were abolished and prevented by a small dose (0.5 mg/kg i.v.) of flumazenil (Ro 15-1788), it is likely that the effects were mediated through activation of benzodiazepine receptors. The results indicate that the hypnotic, zolpidem, has a more potent inhibitory action on SNR cell activity than the anxiolytics, alpidem and diazepam.

Antagonism of ethanol effects by Ro 15-4513: an electrophysiological analysis.

Ethanol (ETH) and general anesthetics have been reported to facilitate the chloride channel opening, possibly, or at least partly, through an interaction with the GABA-benzodiazepine (BZ) receptor-gated chloride ionophore "supramolecular complex". Recently Ro 15-4513, a novel BZ ligand, has been indicated as a potent and selective antagonist of various ETH-induced behavioral and biochemical effects. However, since its precise characterization is still a matter of debate, we have tested and compared the effect of Ro 15-4513, as well as its antagonism against ETH, in two objective electrophysiological parameters, i.e., the electroencephalograph (EEG) pattern in freely moving rats and single unit activity of reticulata neurons. Ro 15-4513 produced an EEG state of alertness and antagonized the behavioral impairment and the EEG deterioration by ETH. However, while its protective action was consistent against moderate doses (2 g/kg) of ETH, it was much less evident versus higher doses (4 and 8 g/kg). On reticulata cells, Ro 15-4513 potently stimulated their spontaneous firing and reversed the depression by both ETH and Na-pentobarbital. Moreover, the beta-carboline DMCM also had similar effects. The "pure" BZ antagonist Ro 15-1788 was completely inefective against ETH, yet fully cancelled the reversing actions of Ro 15-4513 and DMCM upon ETH or Na-pentobarbital effects. It is concluded that Ro 15-4513 behaves as a BZ inverse agonist, so that its opposition to ETH and Na-pentobarbital is probably the result of its "negative" coupling with the BZ recognition site that triggers the closing of chloride channels. It suggests that BZ inverse agonists might constitute, in the near future, a new class of analeptic drugs.